The study of microbiomes is one of the hottest areas in science today. Gerard Honig is a man who wears many hats in this arena, heading a variety of projects related to the field. Hoing founded Symbiotic Health in 2013 which focuses on novel drug delivery solutions as its applied to microbiome therapeutics to solve public health issues. He also is Research Manager at the Chron’s and Colitis Foundation, where they manage a broad array of different projects related to the microbiome.
Join us for an intriguing discussion, as Hoing talks about the challenges and advancements in the field of microbiome science. In this interview he delves into his work on improving the digestive system’s health via the delivery of microbiome-derived proteins; the proteins that target specific pathogenic bacteria within the gut to combat clostridium difficile colitis.
Additionally, Hoing talks about some of the scientific work that Symbiotic Health concentrates on related to the study of specific components of microbiota. Specifically they are focused on the results that can result in therapeutic effects, as well as the potential to apply the research to tackle other disorders of the gut such as inflammatory bowel disease.